Cargando…
Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine
The current vaccine against tuberculosis, Mycobacterium bovis strain bacille Calmette-Guerin (BCG), offers potential advantages as a live, innately immunogenic vaccine vehicle for the expression and delivery of protective recombinant antigens (Stover, C.K., V.F. de la Cruz, T.R. Fuerst, J.E. Burlein...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1993
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2191093/ https://www.ncbi.nlm.nih.gov/pubmed/8315378 |
Ejemplares similares
-
The year that shaped the outcome of the OspA vaccine for human Lyme disease
por: Dattwyler, Raymond J., et al.
Publicado: (2022) -
Tuberculous Orchitis Following Intravesical Bacille Calmette-Guérin (BCG) Therapy
por: Klebanov, Nikolai, et al.
Publicado: (2018) -
Tuberculous Spondylitis after Intrarenal Bacille Calmette-Guerin (BCG) Therapy
por: Kajihara, Yusaku, et al.
Publicado: (2019) -
The safety of co-administration of Bacille Calmette-Guérin (BCG) and influenza vaccines
por: Villanueva, Paola, et al.
Publicado: (2022) -
Essential Role for OspA/B in the Life Cycle of the Lyme Disease Spirochete
por: Yang, Xiaofeng F., et al.
Publicado: (2004)